Lexeo Therapeutics, Inc. · NASDAQ:LXEO

Lexeo Therapeutics — Investor Presentation (November 2026)

37 slides from Lexeo Therapeutics's investor presentation, Nov 16, 2026

  1. Slide 1: Lexeo Therapeutics Corporate Overview November 2026

    Lexeo Therapeutics Corporate Overview November 2026 Exhibit 99.3 1

  2. Slide 2: Forward-looking statements

    Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product

  3. Slide 3: Reshaping the path of genetic disease

    Reshaping the path of genetic disease Our vision: To set a new standard in the treatment of genetic diseases with high unmet need, charting the path to patient outcomes once thought out of reach Genetic disease expertise with cardiovascular and neurological focus Proven experience in the clinic Plat

  4. Slide 4: Pioneering science that fundamentally changes how genetic diseases are treated

    Pioneering science that fundamentally changes how genetic diseases are treated Genetic disease expertise Leader in developing disease-modifying therapies for inherited diseases with high morbidity and mortality Innovative AAV manufacturing Optimized Sf9 baculovirus manufacturing platform designed to

  5. Slide 5: Advancing cardiac and neurological therapies in diseases with high unmet need

    Advancing cardiac and neurological therapies in diseases with high unmet need LX3010 LX2006 LX2020 LX2021 LX2022 LX1001 LX1021 LX1020 ALZHEIMER’S PROGRAMS CARDIAC PROGRAMS FRIEDREICH ATAXIA PROGRAMS PRE-CLINICAL CLINICAL Programs Indication Target Gene Modality Discovery Preclinical Phase I/II Phase

  6. Slide 6: Gene therapy backbone: Highly differentiated capsid supports lead cardiac programs

    Gene therapy backbone: Highly differentiated capsid supports Lexeo’s lead cardiac programs 1 - Selvan, N. et al. Poster presented at: ASGCT Annual Meeting; May 16-20, 2023; Los Angeles, CA. 2 - Ballon DJ et al, Human Gene Therapy, 2020. Note: FXN, Frataxin; LCMS, Liquid chromatography mass spectrome

  7. Slide 7: Gene therapy backbone: optimized Sf9 baculovirus platform

    Gene therapy backbone: Lexeo's optimized Sf9 baculovirus platform combines differentiated manufacturing, attractive economics and demonstrated commercial readiness High yield, strong product quality, and an FDA-endorsed commercial manufacturing process position Lexeo for attractive economics and exe

  8. Slide 8: Two clinical stage gene therapy programs address devastating cardiac diseases

    Lexeo’s two clinical stage gene therapy programs address devastating cardiac diseases FA - Friedreich ataxia; FA-CM - Friedreich ataxia cardiomyopathy; FXN - Frataxin; LVMi - Left ventricular mass index; ACM - arrhythmogenic cardiomyopathy; NSVT - non-sustained ventricular tachycardia; SAP – statist

  9. Slide 9: Friedreich Ataxia Platform Lead Asset: Gene Therapy LX2006

    Friedreich Ataxia Platform Lead Asset: Gene Therapy LX2006 9

  10. Slide 10: Friedreich ataxia is a rare, progressive multisystem disease with significant unmet need

    Friedreich ataxia is a rare, progressive multisystem disease with significant unmet need 1 - Payne R.M. JACC Basic Transl Sci, 2022;13;7(12):1267-1283. 2 - Indelicato, E., et al. Mov Disord, 2024;39(3), 510–518. Cardiac complications are the leading driver of mortality, while neurological decline dr

  11. Slide 11: Timely, multidisciplinary care is critical to managing FA-CM

    Timely, multidisciplinary care is critical to identifying and managing Friedreich ataxia cardiomyopathy (FA-CM) Source: HCP and patient market research. COE, center of excellence. 1 - Norrish G., et al. Friedreich’s ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. 2

  12. Slide 12: LX2006 has potential to treat the root cause of FA-CM

    Gene therapy LX2006 has the potential to treat the root cause of FA-CM: significant decrease in frataxin in the heart AAV, Adeno-Associated Virus; CAG, Chicken Beta-Actin; cDNA, Copy DNA; FA, Friedreich Ataxia; FXN, Frataxin; Poly-A, Poly Adenosine. LX2006 construct: AAVrh.10hFXN Ubiquitous promoter

  13. Slide 13: Elevated LVMi predicts mortality in FA

    Elevated LVMi predicts mortality in FA and is not expected to decrease significantly without intervention HR, Hazard Ratio; CI, Confidence Internal; LVMi, Left Ventricular Mass Index. Note: 10g/m2 represents approximately 10% change in LVMi based on echocardiography measurements of upper bound of no

  14. Slide 14: LX2006 clinical data show sustained or deepening cardiac improvements

    LX2006 clinical data show sustained or deepening improvements across cardiac measures of FA; LX2006 generally well tolerated 1- Participant 11 6-month visit not conducted due to hurricane; 3-month visit used for mean calculations. (2) Participant 10 not included in Hs-TNI chart due to scale. Values

  15. Slide 15: Cardiac function improvement in individual with later stage cardiomyopathy

    Cardiac function improvement observed in individual with later stage cardiomyopathy Baseline LVEF: Normal Post therapy: No change Effect of LX2006 on Cardiac Function Majority of Participants (16/17) Baseline LVEF: Low (35%) Post Therapy: Significant improvements across all cardiac biomarkers One Pa

  16. Slide 16: Sustained neurological improvement with LX2006 at 36 months

    Sustained and deepening neurological improvement observed with LX2006 at 36 months mFARS, Modified Friedreich Ataxia Rating Scale; PSM, propensity score matched. Note: Data as of September 2026; *Participant #3 missed the Month 24 visit; Month 21 data were used instead. 1. 16 patients treated with L

  17. Slide 17: Finalized SUNRISE-FA pivotal protocol and SAP for LX2006

    Finalized SUNRISE-FA 2 pivotal protocol and SAP for LX2006 Vg/kg, vector genomes per kilogram; LVMi, left ventricular mass index; cMRI, cardiac magnetic resonance imaging; mFARS, modified Friedreich Ataxia Rating Scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; Hs, high sensitivity. Study desi

  18. Slide 18: SUNRISE-FA supported by clinical evidence and study design

    SUNRISE-FA 2 is supported by clinical evidence, robust study design and execution readiness 1 -Participant 11 6-month visit not conducted due to hurricane; 3-month visit used for 6 month mean calculation. Observed Phase I/II efficacy exceeds assumptions incorporated into the pivotal study design ~18

  19. Slide 19: FA patients are highly concentrated and readily identifiable

    FA patients are highly concentrated and readily identifiable​ Sources: Data on file. Katharina Buesch & Rongrong Zhang (2022) A systematic review of disease prevalence, health-related quality of life, and economic outcomes associated with Friedreich’s Ataxia, Current Medical Research and Opinion, 38

  20. Slide 20: Strong path forward for LX2006

    Strong path forward for LX2006 Phase I/II Results Exceed the Effect Size in LVMi Used to Power the Pivotal Study Clinical Results SUNRISE-FA 2 Initiated with First Patient Enrolled in June 2026 Clinical Development Building Internal Commercial Capabilities to Support Successful Launch Commercial Pre

  21. Slide 21: Earlier Stage Friedreich Ataxia Programs

    Earlier Stage Friedreich Ataxia Programs

  22. Slide 22: FA platform includes four differentiated approaches to increasing or replacing frataxin

    Lexeo’s FA platform also includes four differentiated approaches to increasing or replacing frataxin for the treatment of FA Plan to prioritize investment on the opportunities with the strongest potential for clinical patient impact, regulatory success and shareholder value creation Program Therapeu

  23. Slide 23: Program highlights: Differentiated oral approaches to increase frataxin

    Program highlights: Differentiated oral approaches to increase frataxin Differentiated oral profile combining robust frataxin upregulation with CNS exposure LX3030 Third-generation oral small molecule (sub-500Da) designed to increase production of endogenous frataxin in the CNS Builds on prior scien

  24. Slide 24: Program highlights: Complementary approaches to restore frataxin

    Program highlights: Complementary approaches to restore frataxin Direct protein replacement diversifies the platform beyond approaches that rely on endogenous frataxin production LX3050 Preclinical recombinant human frataxin fused to a proprietary anti-TfR1 Fab, designed to directly replace deficien

  25. Slide 25: Research collaborations support sequential dosing of CNS-targeted gene therapy

    Lexeo’s research collaborations also support sequential dosing of CNS-targeted gene therapy Sponsored research agreement evaluating intra-cisternal administration of LX2006 following systemic dosing in large animal models. Sequential dosing Option agreement providing the opportunity to secure a lice

  26. Slide 26: Unlocking the full spectrum of FA

    Unlocking the full spectrum of FA LX2006 has the potential to serve as the cardiac foundation of a broader multimodal FA platform addressing both cardiac and neurological disease No cardiomyopathy Neuro-predominant disease Mild CM Diagnosed cardiac involvement Moderate CM Moderate cardiac disease Ad

  27. Slide 27: Plakophilin Arrhythmogenic Cardiomyopathy Gene Therapy LX2020

    Plakophilin 2 Arrhythmogenic Cardiomyopathy Gene Therapy LX2020 27

  28. Slide 28: PKP2 arrhythmogenic cardiomyopathy is a progressive genetic heart disease

    PKP2 arrhythmogenic cardiomyopathy is a progressive genetic heart disease with significant unmet need PKP2-ACM has a clearly defined genetic cause alongside progressive, potentially life-threatening cardiac consequences, with no disease-modifying therapy today Disease overview Rare, genetic cardiac

  29. Slide 29: Significant commercial potential for LX2020

    Significant commercial potential for LX2020 given unmet need and global patient population 60K Patients in the U.S. >$4-6B Total addressable market opportunity Larger-rare, diagnosed population Significant commercial upside at peak Trial ready Broad patient pool expected to support rapid recruitment

  30. Slide 30: Current therapies leave significant unmet need in PKP2-ACM

    *AADs, aanti-arrhythmia drugs; ACM, arrhythmogenic cardiomyopathy. Sources: (1) Daimee et al 2021 n=166. (2) Gaine et al. 2025, N=83. Current therapies may help manage arrhythmias, but limitations in durability, efficacy & tolerability leave a significant unmet need 50% VT recurrence reported within

  31. Slide 31: LX2020 delivers a full-length PKP2 gene to cardiomyocytes

    LX2020 delivers a full-length PKP2 gene to cardiomyocytes, restoring the desmosome PKP2 cDNA (full length gene) Rabbit β-globin polyA AAVrh.10hPKP2 LX2020 construct: Cardiac-specific promoter Promoter PKP2 gene Poly-A PKP2-ACM: LX2020 mechanism: PKP2 expression is expected to restore the balance of

  32. Slide 32: LX2020 ongoing Phase I/II study: HEROIC-PKP2

    LX2020 is being evaluated in an ongoing Phase I/II study: HEROIC-PKP2 2 Key Inclusion Criteria Adults (18-65 years) Diagnosis of ACM with documented PKP2 mutation Existing ICD that is MRI compatible Minimum threshold of PVCs/24-hr Neutralizing anti-AAVrh.10 titer cutoff 1 Study Design & Objective De

  33. Slide 33: Interim LX2020 data show reductions in severe arrhythmia burden

    Interim LX2020 data demonstrate clinically meaningful reductions in severe arrhythmia burden Sources: (1) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385. Note: Data as of October 15, 2026. Participant 3 (low dose) declined 18-month follow up visit but is expected for 24-month follow up. NSVT,

  34. Slide 34: Strong path forward for LX2020

    Strong path forward for LX2020 Meaningful Clinical Activity LX2020 continues to demonstrate improvements across multiple measures of disease burden and patient experience Increasing Confidence in Dataset Additional follow-up strengthens the durability, consistency, and overall benefit-risk profile o

  35. Slide 35: Preclinical Cardiac Programs

    Preclinical Cardiac Programs 35

  36. Slide 36: Lexeo advancing two preclinical cardiac gene therapy programs

    Lexeo is also advancing two preclinical cardiac gene therapy programs +Research collaboration with Johnson & Johnson exploring novel routes of administration for cardiac AAV gene therapy to maximize safety and efficacy Significant unmet need characterized by extensive fibrosis, high arrhythmic risk

  37. Slide 37: Thank you

    Thank you

Lexeo Therapeutics — Investor Presentation (November 2026) on 6ix